IL267195A - - Google Patents
Info
- Publication number
- IL267195A IL267195A IL26719519A IL26719519A IL267195A IL 267195 A IL267195 A IL 267195A IL 26719519 A IL26719519 A IL 26719519A IL 26719519 A IL26719519 A IL 26719519A IL 267195 A IL267195 A IL 267195A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170224 | 2016-12-14 | ||
| PCT/KR2017/014740 WO2018111008A1 (ko) | 2016-12-14 | 2017-12-14 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL267195A true IL267195A (enExample) | 2019-07-31 |
| IL267195B1 IL267195B1 (en) | 2024-01-01 |
| IL267195B2 IL267195B2 (en) | 2024-05-01 |
Family
ID=62559442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267195A IL267195B2 (en) | 2016-12-14 | 2017-12-14 | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11571410B2 (enExample) |
| EP (1) | EP3556366B1 (enExample) |
| JP (1) | JP7208139B2 (enExample) |
| KR (1) | KR102635938B1 (enExample) |
| CN (1) | CN110290788A (enExample) |
| AU (1) | AU2017374458B2 (enExample) |
| BR (1) | BR112019011930A2 (enExample) |
| CL (1) | CL2019001618A1 (enExample) |
| ES (1) | ES3054693T3 (enExample) |
| IL (1) | IL267195B2 (enExample) |
| MX (1) | MX2019006940A (enExample) |
| MY (1) | MY199104A (enExample) |
| WO (1) | WO2018111008A1 (enExample) |
| ZA (1) | ZA201903747B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021003203A (es) * | 2018-09-21 | 2021-05-27 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico. |
| EP3854392A4 (en) * | 2018-09-21 | 2022-08-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES |
| KR20220104746A (ko) * | 2019-11-22 | 2022-07-26 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2297732C (en) * | 1997-08-14 | 2008-04-29 | F. Hoffmann-La Roche Ag | Heterocyclic vinylethers against neurological disorders |
| KR100843703B1 (ko) | 2000-07-21 | 2008-07-04 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 | 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도 |
| CZ20032300A3 (cs) * | 2001-02-27 | 2005-01-12 | Ortho-Mcneil Pharmaceutical, Inc. | Léčivo pro prevenci nebo léčbu bipolárních chorob |
| HUP0303261A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing or treating bipolar disorder |
| AU2005307797B2 (en) * | 2004-11-16 | 2011-06-02 | Alkermes Pharma Ireland Limited | Injectable nanoparticulate olanzapine formulations |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| CA2667909A1 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | Treatment of pervasive developmental disorders |
| BRPI0924997B1 (pt) | 2009-06-22 | 2024-01-16 | Sk Biopharmaceuticals Co., Ltd | Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9981950B2 (en) * | 2014-08-15 | 2018-05-29 | Janssen Pharmaceuticals, Inc. | Triazoles as NR2B receptor inhibitors |
-
2017
- 2017-12-14 JP JP2019531623A patent/JP7208139B2/ja active Active
- 2017-12-14 AU AU2017374458A patent/AU2017374458B2/en active Active
- 2017-12-14 BR BR112019011930-2A patent/BR112019011930A2/pt not_active Application Discontinuation
- 2017-12-14 MY MYPI2019003348A patent/MY199104A/en unknown
- 2017-12-14 EP EP17881161.8A patent/EP3556366B1/en active Active
- 2017-12-14 CN CN201780077574.0A patent/CN110290788A/zh active Pending
- 2017-12-14 US US16/468,782 patent/US11571410B2/en active Active
- 2017-12-14 WO PCT/KR2017/014740 patent/WO2018111008A1/ko not_active Ceased
- 2017-12-14 IL IL267195A patent/IL267195B2/en unknown
- 2017-12-14 KR KR1020197018408A patent/KR102635938B1/ko active Active
- 2017-12-14 MX MX2019006940A patent/MX2019006940A/es unknown
- 2017-12-14 ES ES17881161T patent/ES3054693T3/es active Active
-
2019
- 2019-06-11 ZA ZA2019/03747A patent/ZA201903747B/en unknown
- 2019-06-12 CL CL2019001618A patent/CL2019001618A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3556366A1 (en) | 2019-10-23 |
| RU2019121913A (ru) | 2021-01-15 |
| JP2020502106A (ja) | 2020-01-23 |
| ZA201903747B (en) | 2021-01-27 |
| WO2018111008A1 (ko) | 2018-06-21 |
| KR102635938B1 (ko) | 2024-02-13 |
| CL2019001618A1 (es) | 2019-08-23 |
| AU2017374458B2 (en) | 2023-03-02 |
| US11571410B2 (en) | 2023-02-07 |
| RU2019121913A3 (enExample) | 2021-04-21 |
| EP3556366A4 (en) | 2020-06-17 |
| IL267195B2 (en) | 2024-05-01 |
| KR20190087572A (ko) | 2019-07-24 |
| CA3046297A1 (en) | 2018-06-21 |
| BR112019011930A2 (pt) | 2019-10-29 |
| EP3556366B1 (en) | 2025-10-22 |
| CN110290788A (zh) | 2019-09-27 |
| US20190314337A1 (en) | 2019-10-17 |
| ES3054693T3 (en) | 2026-02-05 |
| IL267195B1 (en) | 2024-01-01 |
| MY199104A (en) | 2023-10-13 |
| MX2019006940A (es) | 2019-09-06 |
| AU2017374458A1 (en) | 2019-07-04 |
| JP7208139B2 (ja) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019002665A2 (enExample) | ||
| BR112018004986A2 (enExample) | ||
| BR112019008105A2 (enExample) | ||
| BR112019001429A2 (enExample) | ||
| IL267192A (enExample) | ||
| BR212018070320U2 (enExample) | ||
| BR112019011044B1 (pt) | Compostos de pirazol substituído, seu uso, e composição farmacêutica | |
| BR112019008501B1 (pt) | Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador | |
| BR112019003116B1 (pt) | Configuração de símbolo de rajada comum de uplink | |
| BR112018076493B1 (pt) | Sistemas e métodos para detecção de posição de feixe de luz | |
| BR112018073794B1 (pt) | Partícula, método de geração da partícula, vacina ou composição farmacêutica | |
| BR122026002520A2 (pt) | Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno | |
| BR112019006736A2 (enExample) | ||
| BR102016018018A2 (enExample) | ||
| BE2016C016I2 (enExample) | ||
| CN303538222S (enExample) | ||
| CN303606453S (enExample) | ||
| CN303536207S (enExample) | ||
| CN303537291S (enExample) | ||
| CN303536593S (enExample) | ||
| CN303536111S (enExample) | ||
| CN303537591S (enExample) | ||
| CN303536221S (enExample) | ||
| CN303645752S (enExample) | ||
| CN303536491S (enExample) |